Treatment of severe recalcitrant plaque psoriasis with single-dose intravenous tumour necrosis factor-alpha antibody (infliximab)

Australasian Journal of Dermatology

Volumn 44, Issue 2, 2003, Pages 116-120

  Chan, Jonathan J ^a,c   Gebauer, Kurt ^b  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b FREMANTLE HOSPITAL   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Psoriatic arthritis; Quality of life; Remission; Single dose therapy

Indexed keywords

CHIMERIC ANTIBODY; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ANAPHYLAXIS; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MALE; NAUSEA; PSORIASIS VULGARIS; SIDE EFFECT; SINGLE DRUG DOSE; TACHYCARDIA; TREATMENT OUTCOME; URTICARIA;

ADULT; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PROSPECTIVE STUDIES; PSORIASIS; QUALITY OF LIFE; RISK ASSESSMENT; SAMPLING STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0038017157     PISSN: 00048380     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-0960.2003.00656.x     Document Type: Article

References (26)

1. Greaves MW, Weinstein GD. Treatment of psoriasis. N. Engl. J. Med. 1995; 332: 581-8.
2. Baker BS, Swain AF, Fry L, Valdimarsson H. Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br. J. Dermatol. 1984; 110: 555-64.
3. Mueller W, Herrmann B. Cyclosporine A For psoriasis. N. Engl. J. Med. 1979; 301: 555-7.
4. Weinstein GD, McCullough JL. Cytokinetics and chemotherapy of psoriasis. J. Invest. Dermatol. 1976; 67: 26-8.
5. Bonifati C, Amegliio F. Cytokines in psoriasis. Int. J. Dermatol. 1999; 38: 241-51.
6. Nickoloff BJ. The cytokine network in psoriasis. Arch. Dermatol. 1991; 127: 871-84.
7. Gilhar A, David M, Kalish RS, Weisinger G. In vivo effects of cytokines on psoriatic skin grafted on nude mice: Involvement of the tumour necrosis factor (TNF) receptor. Clin. Exp. Immunol. 1996; 106: 134-42.
8. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J. Am. Acad. Dermatol. 2000; 42: 829-30.
9. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial. Lancet 2001; 357: 1842-7.
10. Girolomoni G, Abeni D. Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis. Arch. Dermatol. 2001; 157: 784-5.
11. O'Quinn RP, Miller JL. The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: A report of 2 cases. Arch. Dermatol. 2002; 138: 644-8.
12. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J. Am. Acad. Dermatol. 2002; 46: 886-91.
13. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin. Exp. Dermatol. 1994; 19: 210-16.
14. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arth. Rheum. 1998; 41: 1552-63.
15. Kalden JR. Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases. Arth. Res. 2002; 4 (Suppl. 2): S34-40.
16. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol. 1993; 30: 1445-55.
17. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995; 7: 251-9.
18. Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999; 116: 22-8.
19. Lorenz HM, Antoni C, Valerius T, Repp R, Grunke M, Schwerdtner N, Nusslein H, Woody J, Kalden JR, Manger B. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. J. Immunol. 1996; 156: 1646-53.
20. Paleolog E. Target effector role of vascular endothelium in the inflammatory response: Insights from the clinical trial of anti-TNF alpha antibody in rheumatoid arthritis. Mol. Pathol. 1997; 50: 225-33.
21. Paleolog E. Remicade: Hospital Formulary Submission. Sydney: Schering-Plough Pry Ltd, 2000.
22. Ogilvie AL, Antoni C, Dechant C, Manger B, Kalden JR, Schuler G, Luftl M. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br. J. Dermatol. 2001; 144: 587-9.
23. Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: An open pilot study. Ann. Rheum. Dis. 2000; 59: 428-33.
24. Van Den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, Veys EM. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arth. Rheum. 2002; 46: 755-65.
25. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 2001; 345: 1098-104.
26. Hohler T, Grossmann S, Stradmann-Bellinghausen B, Kaluza W, Reuss E, de Vlam K, Veys E, Marker-Hermann E. Differential association of polymorphisms in the TNF alpha region with psoriatic arthritis but not psoriasis. Ann. Rheum. Dis. 2002; 61: 213-18.